cardiology careers collections past issues search home
     

J Am Coll Cardiol, 2008; 51:1104-1109, doi:10.1016/j.jacc.2007.09.071
© 2008 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow View Online Appendix
Right arrow Correction (v51,p1525)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (2)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ibanez, B.
Right arrow Articles by Badimon, J. J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Ibanez, B.
Right arrow Articles by Badimon, J. J.
Related Collections
Right arrowRelated Article

PRECLINICAL STUDY: APO: A-IMILANO

Rapid Change in Plaque Size, Composition, and Molecular Footprint After Recombinant Apolipoprotein A-IMilano (ETC-216) Administration

Magnetic Resonance Imaging Study in an Experimental Model of Atherosclerosis

Borja Ibanez, MD*, Gemma Vilahur, DVM, PhD{dagger}, Giovanni Cimmino, MD*, Walter S. Speidl, MD*, Antonio Pinero, MD*, Brian G. Choi, MD*, M. Urooj Zafar, MD*, Carlos G. Santos-Gallego, MD*, Brian Krause, PhD{ddagger}, Lina Badimon, PhD{dagger}, Valentin Fuster, MD, PhD, FACC* and Juan J. Badimon, PhD, FACC*

* Cardiovascular Biology Research Laboratory, Cardiovascular Institute, Mount Sinai School of Medicine, New York, New York
{dagger} Cardiovascular Research Center, CSIC-ICCC, Hospital de la Santa Creu i Sant Pau, UAB, Barcelona, Spain
{ddagger} Pfizer Research and Development, Groton, Connecticut.

Manuscript received July 3, 2007; revised manuscript received September 10, 2007, accepted September 17, 2007.

* Reprint requests and correspondence: Dr. Juan J. Badimon, Mount Sinai School of Medicine, One Gustave L. Levy Place, Box 1030, New York, New York 10029. (Email: juan.badimon{at}mssm.edu).

Objectives: This study sought to assess the effect of short-term apolipoprotein (apo) A-IMilano administration on plaque size and on suspected markers of plaque vulnerability.

Background: Long-term lipid-lowering interventions can regress and stabilize atherosclerotic plaques. However, the majority of recurrent events occur early after the first episode. Interventions able to acutely induce plaque regression and stabilization are lacking. Regression of human coronary lesions after 5 weeks of treatment with apoA-IMilano administration has been shown. However, there are no data regarding its effect on plaque vulnerability.

Methods: Advanced aortic lesions were induced in New Zealand White rabbits (n = 40). Plaque size was assessed by magnetic resonance imaging (MRI) at the end of atherosclerosis induction. Animals were randomized to placebo or apoA-IMilano phospholipids (ETC-216), 2 infusions 4 days apart. After the last dose, another MRI study was performed and aortas were processed for cellular composition and gene protein expression of markers associated with plaque instability.

Results: Pre-treatment MRI showed similar plaque size in both groups, whereas post-treatment MRI showed 6% smaller plaques in apoA-IMilano–treated animals compared with placebo (p = 0.026). The apoA-IMilano treatment induced a 5% plaque regression (p = 0.003 vs. pre-treatment), whereas the placebo showed no significant effect. Plaque regression by apoA-IMilano was associated with a reduction in plaque macrophage density and a significant down-regulation in gene and protein expression of tissue factor, monocyte chemoattractant protein-1, and cyclooxygenase-2, as well as marked decrease in gelatinolytic activity. Conversely, cyclooxygenase-1 was significantly up-regulated.

Conclusions: Acute plaque regression observed after short-term apoA-IMilano administration was associated with a significant reduction in suspected makers of plaque vulnerability in an experimental model of atherosclerosis.

Abbreviations and Acronyms
  apo = apolipoprotein
  CETP = cholesteryl ester transfer protein
  COX = cyclooxygenase
  ETC-216 = recombinant apolipoprotein A-IMilano and 1-palmitoyl-2-oleoyl phosphatidylcholine complexes
  HDL = high-density lipoprotein
  MCP = monocyte chemoattractant protein
  MMP = matrix metalloproteinase
  MRI = magnetic resonance imaging
  rApoA-IM = recombinant apolipoprotein A-IMilano
  TF = tissue factor


Related Article

ApoA-IMilano/Phospholipid Complex: Clinical Implications of Dose-Response Studies in Rabbit Atherosclerosis With Intravascular Ultrasound and Magnetic Resonance Imaging
Xue-Qiao Zhao and B. Greg Brown
J. Am. Coll. Cardiol. 2008 51: 1110-1111. [Full Text] [PDF]



This article has been cited by other articles:


Home page
Circ. Res.Home page
J. A. Shaw, A. Bobik, A. Murphy, P. Kanellakis, P. Blombery, N. Mukhamedova, K. Woollard, S. Lyon, D. Sviridov, and A. M. Dart
Infusion of Reconstituted High-Density Lipoprotein Leads to Acute Changes in Human Atherosclerotic Plaque
Circ. Res., November 7, 2008; 103(10): 1084 - 1091.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
X.-Q. Zhao and B. G. Brown
ApoA-I(Milano)/phospholipid complex: clinical implications of dose-response studies in rabbit atherosclerosis with intravascular ultrasound and magnetic resonance imaging.
J. Am. Coll. Cardiol., March 18, 2008; 51(11): 1110 - 1111.
[Full Text] [PDF]



 
  cardiology careers collections past issues search home